Greece vs Guinea-Bissau: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Greece
89.0%
in 2025
Guinea-Bissau
90.0%
in 2025
Greece rank
70th
Guinea-Bissau rank
68th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Greece
- Guinea-Bissau
How they compare
Guinea-Bissau currently reports 90.0% against 89.0% in Greece, a difference of 1.0%.
The two have swapped places 2 times across 18 shared years of data; in 2008 it was Guinea-Bissau ahead.
Greece ranks 70th and Guinea-Bissau ranks 68th of 192 countries.
Greece has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Greece | Guinea-Bissau | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 64.0% | 34.1% | 29.9% | Greece |
| 2020s | 92.3% | 85.5% | 6.8% | Greece |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Greece or Guinea-Bissau?
- Guinea-Bissau, at 90.0% against 89.0% in Greece as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Greece and Guinea-Bissau?
- 1.0%, with Guinea-Bissau ahead.
- How many years of comparable data are there for Greece and Guinea-Bissau?
- 18 years are reported by both, from 2008 to 2025.
- How do Greece and Guinea-Bissau rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Greece ranks 70th and Guinea-Bissau ranks 68th of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.